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Abstract 
 
 Long-chain 3-Hydroxyacyl CoA Dehydrogenase Deficiency (LCHADD) is an autosomal 
recessive defect in fatty acid oxidation that presents with hypoketotic hypoglycemia and/or 
hypertrophic cardiomyopathy in infancy, and recurrent rhabdomyolysis in adolescence, however, 
sudden cardiac death has not been a previously reported complication of LCHADD. We have 
conducted a case review study comparing young adult LCHADD patients who have experienced 
sudden cardiac arrest events (n=5) to similar patients who have not (n=5) for the purpose of 
evaluating associated cardiac risk factors. We reviewed medical records from ECG tests, 
hospitalization reports, acylcarnitine, and complete metabolic panels, clinic notes, and autopsy 
reports. Retrospective chart review has led to no certain etiology however, electrolyte 
derangements, low free carnitine and elevated total to free carnitine ratio have been noted upon 
hospitalization in sudden cardiac arrest cases. At the time of the sudden cardiac death event, only 
one subject was in a metabolic crisis with elevated creatine phosphokinase levels. Life-
threatening ventricular arrhythmias appear to be a newly recognized life-threatening 
complication in the adolescent and young adult age groups of LCHADD patients. The exact 
mechanism underlying the sudden death events is not understood and there are no current 
therapies. Understanding the pathophysiology of inherited arrhythmias can be challenging due to 
the complexity of both the heart and LCHAD deficiency along with the lack of appropriate 
cellular and in vivo models. Recent advances in human-induced pluripotent stem cell (hiPSC) 
technology have provided extraordinary progress in understanding the mechanisms in generating 
human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Future directions of 
this study seek to generate LCHAD deficient patient-derived iPSC-CMs in order to assess 
mitochondrial function, force of contraction, oxygen consumption rates, impacts of analytes, and 
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calcium regulation. In a paper published in the Nature Methods Journal, Burridge and colleagues 
establish an easily reproducible protocol for the chemically defined generation of human 
cardiomyocytes (Burridge, Matsa, & Shukla, 2014) from skin fibroblast-derived induced 
pluripotent stem cells. Our research lab will establish this method which utilizes three crucial 
components of a chemically defined medium consisting of the basal medium RPMI 1640, L-
ascorbic acid 2-phosphate along with recombinant human albumin to generate cardiomyocytes 
with an immature phenotype. This chemically defined medium will provide reproducible, 
scalable methods for deriving cardiomyocytes from iPSCs however, they do remain immature in 
nature and future directions of the study seek to adapt newly engineered maturation protocols. 
Assessing the disruption of bioenergetics and mitochondrial function in hiPSC-CMs will provide 
a meaningful in vitro model to examine the potential pathways and biochemical mechanisms that 
contribute to cardiac arrhythmias observed in affected LCHADD patients who have experienced 
sudden cardiac death events. Ultimately, clinical trials will be needed to further characterize the 
pathophysiology of these severe cardiac manifestations in young adult LHCADD populations.  
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Introduction 
Fatty Acid (FA) Metabolism 
  
 Metabolism is an essential process that occurs in every living organism. It’s a term that 
describes all the chemical reactions that occur within living cells that function to either convert 
food into energy through a process of catabolism or to convert small nutrients into large 
molecules through anabolism. In living organisms, fatty acids (FAs) are critical and essential fuel 
sources in the body that consist of certain fats we obtain through the food we consume. When 
digestion occurs, the body breaks down fats into fatty acids which can then be absorbed into the 
blood and transported throughout the body. Fatty acids have many important functions in the 
body including energy storage, maintenance of cellular membranes, and as a major source of 
fuel. Lipolysis of fats in the body is a biochemical process that occurs in the cytoplasm of a cell 
where large FAs such as triglycerides can be broken down into smaller substituents of glycerol 
and three molecules of FAs which enter the mitochondria to further metabolism. Three types of 
fatty acid oxidation processes that occur in the body include mitochondrial-β oxidation, 
microsomal ω-oxidation, and peroxisomal β-oxidation which all differ vastly from each other. 
Mitochondrial beta-oxidation is one of the most crucial pathways in living organisms that 
oxidize the released FAs from triglycerides into two carbon units of acetyl CoA. Fatty acid 
oxidation (FAO) occurs through an orchestration of over 20 different enzymes that form the 
pathway and allow oxidation to occur. The movement and shuttling of FAs from the cytosol into 
the mitochondria for oxidation are credited to a set of enzymes known as carnitine palmitoyl-
transferase shuttles. Long-chain fatty acyl-CoA enters the outer membrane of the mitochondria 
and is converted to a long-chain fatty acyl-carnitine by carnitine palmitoyl-transferase 1. The 
fatty acylcarnitine is transported into the mitochondria by carnitine palmitoyl-transferase and the 
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fatty acyl-CoA is reformed by carnitine palmitoyl-transferase II allowing for further oxidation 
and the crucial steps of beta-oxidation occur.  
Mitochondrial β-Fatty Acid Oxidation  
 
 Beta oxidation produces a lot of ATP allowing living cells to meet high energy demands 
and, maintain internal homeostasis, especially during variations in internal or external 
environmental conditions.  Conditions that increase cellular energy needs include disease, 
exercise and durations of fasting. Oxidation of fatty acids is necessary to meet these energy 
demands and requires a series of complex enzymes one of which is, the mitochondrial 
trifunctional protein (MTP). MTP is a multienzyme complex situated in the inner mitochondrial 
membrane that is constituted of four alpha subunits, and four beta subunits. The HADHA gene 
encodes the alpha subunit of the MTP complex and the HADHB gene encodes the beta subunit 
of the MTP complex which are responsible for catalyzing the last three steps of mitochondrial 
beta-oxidation of long-chain fatty acids (LCFAs). The HADHA gene is responsible for 
catalyzing the 3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities whereas 
the HADHB gene is responsible for catalyzing the 3-ketoacyl-CoA thiolase activity. A number 
of fatty acid oxidation disorders (FAODS) are caused by genetic defects in the enzymes 
responsible for the transport of fatty acids in the mitochondria and for the oxidation of fatty acids 
in the mitochondria (Wilcken, 2010). A deficiency of any one of the enzymes listed above, could 
cause direct blocks in crucial pathways of fatty acid oxidation resulting in FAODs. Organs that 
particularly rely on FAO include the liver, eyes, muscle, and the heart which can become 
severely adversely affected by FAODs that block these processes from properly occurring 
(Wajner, 2016).  
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Fatty Acid Oxidation Disorders (FAODs) 
  
FAODs are autosomal recessively inherited disorders which is one of several ways that a 
disease can be passed through families throughout generations. For autosomal recessive 
inheritance to occur, two copies of a gene in a cell are mutated and each parent will carry one 
copy of the mutated gene however, they typically do not present with any symptoms of the 
condition which implies that we can see the disease skip through generations in a family. Some 
of the common FAODs include short-chain acyl-CoA dehydrogenase (SCAD), medium-chain 
acyl-CoA dehydrogenase (MCAD), long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD), 
and very long-chain acyl-CoA dehydrogenase (VLACD) deficiencies. Of these enzyme 
deficiencies, the four most prevalent deficiencies in the long-chain fatty acid oxidation pathway 
are CPT-II, VLCAD, LCHAD, and MTP deficiencies. Figure 1 below includes the details of 
presentation and diagnostic criteria of the long-chain fatty acid deficiencies. 
 
Figure 1. A table indicating the various long-chain fatty acid oxidation disorders and their typical 
presentations and diagnosis (Merritt, 2018) 
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Initial presentations of several FAODs are seen in the neonatal period with severe 
symptoms including hypoketotic hypoglycemia, cardiomyopathy, liver dysfunction, and 
retinopathy which are common and sometimes, also continue to present into infancy and early 
childhood. Episodic rhabdomyolysis is the breakdown of damaged skeletal muscle which causes 
the release of myoglobin. This release results in extreme pain in patients and is a frequent 
presentation during or after adolescence in those with long-chain FAODs (Merritt, 2018). 
Research suggests that individuals with FAODs accumulate toxic byproducts in the blood stream 
such as long-chain fatty and hydroxy acids, and fatty acyl-carnitines. Newborns with FAOD tend 
to experience multi-organ failure of varying severities which can become worse under stressed 
conditions that exacerbate energy use especially during times of fasting, illness or with 
prolonged exercise.  
Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency 
 
Long-chain 3-Hydroxyacyl-Coenzyme A Dehydrogenase deficiency (LCHADD) is part 
of the fatty acid oxidation disorders (FAOD) family of disorders. LCHADD is the result of a 
mutation in the alpha subunit of the MTP, HADHA. Mutation in the active site residue of the 
HADHA gene (1528G>C) is responsible for the loss of LCHAD enzyme activity. Classic 
symptoms of infants with LCHADD include recurrent hypoglycemia induced by fasting or 
physiologic stress, and recurrent rhabdomyolysis or exercise intolerance which can also induce 
overwhelming neonatal cardiomyopathy in young children and infants (Vockley, 2017). 
Newborn screening (NBS) for fatty acid oxidation disorders, including LCHADD, was started in 
Oregon in 2004. Today, most infants have the opportunity to become diagnosed at an early age 
allowing for prompt medical care before a catastrophic metabolic decompensation occurs 
(Frazier, 2006). 
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Prior to the advent of NBS, hypertrophic and dilated cardiomyopathy in infants was a 
frequently documented complication of LCHADD. Upon diagnosis and treatment, the 
cardiomyopathy typically resolves and patients have reported normal cardiac function in 
childhood. However, recently, there have been 7 known cases of sudden ventricular tachycardia 
(VT) in adolescent and young adults with LCHADD between 16 and 23 years of age. Acute VT 
in the absence of hypertrophic cardiomyopathy appears to be a late complication observed in 
some adolescent and young adults with LCHADD that is not currently described in the literature. 
At a scientific meeting in 2013, our research group reported a short case series (3 
subjects) of patients with LCHADD who had experienced sudden cardiac arrest events. Since 
then, 4 other cases have appeared.  Medical records of 5 patients with LCHADD and sudden 
cardiac arrest have been reviewed. Of these patients, 4 were resuscitated and 1 was deceased. 
Three patients received an implantable cardioverter. Medical records of 5 patients with 
LCHADD of similar age who have not had a cardiac arrest were also reviewed and utilized for 
comparison. While electrolyte derangements are reported in the record, we hypothesize that 
unidentified underlying cardiac risk factors that increase the risk for sudden cardiac arrest may 
exist. To date, there are 7 known or suspected cases of sudden VT in adolescent and young 
adults with LCHADD in an estimated population of 60 patients >16 years of age in the U.S., thus 
becoming a significant medical problem for this specific patient population. Sudden cardiac 
arrest episodes have also become of concern to other patients with LCHADD and their families, 
who are now enquiring whether prophylactic implantable cardioverters should be considered for 
primary prevention of a sudden VT event in young adult LCHADD patients. A thorough cardiac 
evaluation has not been performed among these patients and specific risk factors have not yet 
been identified. A recent grant and IRB study submission to conduct more thorough cardiac 
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evaluation for patients described here was submitted and approved. Recruitment was about to 
start but due to the impacts of COVID-19, the study enrollment was postponed an indefinite 
amount of time. The lack of thorough cardiac data from this extremely rare and limited study 
population and the lack of an appropriate cellular model are two of the essential motivations 
behind the current line of research into sudden cardiac death in LCHADD patients.  
Central Hypothesis, Purpose, and Specific Aims  
 
Establishing a cellular model to further research sudden cardiac death in LCHADD 
patients is a major goal of this study which will also entail additional protocols and materials to 
generate cardiomyocytes with a mature phenotype that are capable of oxidizing fatty acids. In a 
paper published in the Nature Methods Journal, Burridge and colleagues establish a reproducible 
protocol for the chemically defined generation of human cardiomyocytes from skin fibroblast 
derived, induced pluripotent stem cells. This protocol was adapted by our lab to generate 
cardiomyocytes with an immature phenotype which was successful prior to the institution of 
modified research due to the COVID-19 pandemic. 
The initial stage of cardiomyocyte generation involves three crucial components of a 
chemically defined medium consisting of the basal medium RPMI 1640, L-ascorbic acid 2-
phosphate along with recombinant human albumin, and small-molecules responsible for cellular 
signaling. This chemically defined medium will provide a reproducible, scalable method for 
deriving cardiomyocytes from human induced pluripotent stem cells that begin immature and 
fetal like in nature. In another study, a research group from the University of Washington School 
of Medicine generated matured human induced pluripotent stem cell cardiomyocytes (hiPSC-
CMs) by engineering a microRNA maturation cocktail known as MiMaC consisting of Let7i OE, 
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miR-452 OE, miR-122 KO, and miR-200a KO which greatly reduced the complete time of the 
protocol. One of the key differences during maturation is the switch from glycolysis to oxidative 
phosphorylation for energy production, including fatty acid oxidation. Once mature hiPSC-CMs 
have been generated, our study will aim to assess the functionality of hiPSC-CMs by measuring 
and comparing force of contraction, oxygen consumption rates, beat rates, and calcium 
regulation in LCHADD patient derived iPSC-CMs compared to normal healthy iPSC-CMs.  
Other studies have also suggested that accumulation of long-chain hydroxyl acyl-CoA 
esters and/or the long chain 3-hydroxylated fatty acids (LCHFA) and particularly, 3-
hydroxypalmitic acid (3HPA) in patients can have an effect on mitochondrial respiratory 
parameters measured by oxygen consumption in intact cell system consisting of heart fibers, 
cardiomyocytes, hepatocytes, and brain slices (Cecatto, Wajner, Vargas, 2018). This research has 
explored the potential effects of pathological concentrations of toxic byproducts (LCHFAs and 
3HPAs) formed by LCHADD patients postulating toxicity as one particular mechanism of 
sudden ventricular death in this population. When the LCHAD enzyme is missing, accumulated 
levels of long-chain 3-hydroxylated fatty acids (LCHFA), particularly 3-hydroxypalmitic acid 
(3HPA) and their carnitine conjugates can be seen in patients’ bloodstream. Diagnoses of 
mitochondrial fatty acid oxidation disorders like LCHADD are typically based on increased 
concentrations of long-chain 3-hydroxyacylcarnitines in plasma and excessive urinary excretion 
of 3-hydroxy-carboxlyic acids, especially during or after a metabolic decompensation (den Boer, 
2002). Symptoms often develop in the presence of episodes of illness or fasting which affect 
organs that predominantly use long-chain fatty acids for means of energy such as the heart, liver, 
retinal, and skeletal muscle.  
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An additional avenue to the current study is to investigate the effects of LCHAD 
deficiency and the presence of long-chain 3-hydroxylated fatty acids, (which accumulates the 
most in LCHAD deficiency), on mitochondrial respiratory parameters measured by oxygen 
consumption, and cardiac electrophysiology in intact cell systems of human induced pluripotent 
derived stem cells that have been differentiated into cardiomyocytes. Measurement of other 
crucial mitochondrial functions including membrane potential, Ca2+ retention capacity, beat force 
and contraction rate, in cardiomyocytes derived from LCHAD patients who have and have not 
experienced severe cardiac death events will be useful in our exploration.  
The answers to the following research questions is what the study seeks to explore: 
- How are mitochondrial parameters such as oxygen consumption and various cardiac 
electrophysiological functions affected in LCHAD deficient patient derived, induced 
pluripotent stem cells differentiated into cardiomyocytes? 
- How may the pathological concentrations of long chain 3-hydroxylated acids such as 
3HPA affect bioenergetics and overall function of LCHAD deficient, mature 
cardiomyocytes? 
Patients 
 
Adolescent and young adult patients with confirmed LCHAD deficiency having 
consented, in compliance with the Helsinki Declaration, to the collection and use of their medical 
records for future research through our “Fatty Acid Oxidation Disorders Tissue Repository” 
(IRB #8561) were enrolled in this retrospective case study (IRB #18446). Medical records 
including results assessed from electrocardiogram (ECG) tests, hospitalization reports, 
acylcarnitine and complete metabolic panels, clinic and laboratory notes, and autopsy reports 
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were obtained for review. Medical records of 10 patients were reviewed and patients split into 
two groups according to whether they had a history of sudden cardiac arrest (SCA) (N=5) or had 
no history of SCA (‘controls’, N=5). In patients with a history of SCA, 4 were resuscitated and 1 
is deceased following SCA. Age range at 1st cardiac event was 15-21 years, with current age at 
time of review of 19-27 years. In ‘controls’ without history of SCA, 2 died of cardiac 
abnormalities not related to SCA. Current age ranges of ‘controls’ at time of review was 19-25 
years. 
Methodology 
 
Skin fibroblasts obtained from LCHADD patients in a separate IRB protocol (IRB#8561) 
can be used to generate induced pluripotent stem cells. Fibroblasts are reprogrammed in our lab 
by integration-free Sendai virus vectors which can then induce the formation of stem cells. 
hiPSCs can then be differentiated and used for further experiments. Our research lab has 
experience differentiating iPSCs to human retinal pigmented epithelial cells however, generation 
of hiPSC derived cardiomyocytes has not yet been attempted. It is our hope to establish a reliable 
protocol to differentiate hiPSCs to mature cardiomyocytes in order to carry out experiments that 
concern the electrophysiology and overall function of LCHAD deficient cardiomyocytes. This 
will provide an in vitro model to investigate potential mechanisms associated with arrythmias in 
human patients. Through the establishment of a cellular model, we hope this will provide a 
critical research tool that has the potential to further understand the mechanisms of arrythmias in 
patients.  
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Cell Cultures 
 
Skin fibroblasts derived from patients and other similar somatic cell types lack high 
expression of the transcription Oct4, Sox2, Klf4, and c-Myc under normal condition. Once high 
levels of expression for these four genes are achieved, a fibroblast can become reprogrammed to 
pluripotent cell types. Induced pluripotent stem cells (iPSC) are genetically reprogrammed adult 
cells which exhibit a pluripotent stem cell-like state similar to embryonic stem cells (Takahashi 
et al., 2007). There are multiple ways of generating iPSCs which include retrovirus-mediated 
gene transduction and chemical induction. DNA-based vectors that include adenovirus, or 
plasmid vectors do not require integration into the hosts chromosomes and therefore allow the 
cells to reprogram with non-integrating episomal DNA vectors. Sendai virus is a single stranded 
negative-sense RNA virus that replicates in the cytoplasm and produces very high copy numbers 
of the target gene. The Sendai viral vector can be used to efficiently express all four factors 
stably without chromosomal integration and can be eliminated completely from reprogrammed 
skin fibroblast cells. Once iPSCs have been generated, cells can be inducted into three different 
potential layers that include the ectodermal (neuron, astrocytes, Retinal Epithelial cells (RPE)), 
endodermal (lung, thyroid, pancreatic cells), or into the mesoderm layer (cardiac and skeletal 
muscle cells, tubule cells of the kidney, or red blood cells) (Millipore Sigma, 2016). 
Cardiomyocyte Differentiation 
 
To further reveal the disease etiology of the sudden cardiac death events we will 
differentiate induced pluripotent stem cells (iPSCs) into cardiomyocytes which will inherit the 
genetics found in skin fibroblasts from LCHAD deficient patients that were enrolled into the 
study rendering these CMs as LCHAD deficient. In the past decade, many methods have been 
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developed that successfully differentiate iPSCs into cardiomyocytes. While this study seeks to 
establish an in vitro model to study potential mechanisms of SCD, this model is anticipated to 
still be largely limited in its implications to be made in relation to LCHADD patients who 
experience differences in physiology, course of medical history, and compliance to diet. 
Advantages of using hiPSC-CMs include their ability to replicate the genome of the patient 
donor to allow for characterization of numerous disease states and drugs, as well as their ability 
to contract which allows for a model of cardiac contractility and electrophysiology. Despite the 
ability to model biochemical mechanisms in one’s body, this approach is still highly limited in 
being able to translate the results in human subjects. 
hiPSC-CMs also have limitations due to their immaturity as they represent fetal 
cardiomyocytes instead of full-functioning, adult cardiomyocytes. A protocol adapted from 
Burridge and colleagues will be utilized in this experiment to generate an initial and immature 
cardiomyocyte model. Though this model has been adequately optimized to generate beating 
iPSC-CMs, the resulting cells remain highly immature in their nature in regards to their structure 
and function. These immature cardiomyocytes which rely on glycolysis to produce energy 
(instead of fatty acid utilization), experience reduced contractile and electrophysiological 
function and structure, and exhibit disorganized morphologies. Recent research has established 
that disease modelling using immature iPSC-CMs may be inaccurate and limited in their utility, 
particularly for investigating the impacts of a defect in fat oxidation. This weakness in the 
literature has been widely addressed and numerous groups have made efforts to establish 
methods of maturing cardiomyocytes. We will aim to review and replicate successful methods 
that have been developed for the maturation of human iPSC-CMs using small molecules, 
environmental manipulation, prolonged cell-culturing, or 3-dimensional growth approaches.  
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The same research group at the University of Washington recently published a paper 
addressing a successful method of maturing iPSC-CMs through addition of small molecules and 
environmental manipulation approaches of matured iPSC-CMs (Miklas, Clark, Levy, & Detraux, 
2019). The research group engineered a microRNA maturation cocktail known as MiMaC 
consisting of mix of specific micro-RNAs that alter gene expression: Let7i OE, miR-452 OE, 
miR-122 KO, and miR-200a KO. Upon functional assessment of cardiomyocytes treated with 
MiMaC, an increase in parameters such as twitch force, power, cell area, and the ability to utilize 
palmitate more efficiently than control CMs was reported. Once mature phenotype exhibiting 
hiPSC-CMs have been generated that exhibit optimal mechanical and electrical stimulation, 
further studies of cell bioenergetics and mitochondrial function can be properly assessed. 
Platforms for Functional Analysis of hiPSC-CMs 
  
 Using iPSC technology, we will produce a model of LCHADD patient specific 
cardiomyocytes to investigate potential mechanisms for sudden conduction arrhythmias. A 
crucial step for this procedure will be to characterize and confirm gene expression patterns and 
comparing mRNA levels in samples of cardiomyocytes that are produced. Measuring and 
characterizing the mRNA expression in cardiomyocytes will entail the use of quantitative 
polymerase chain reaction (qPCR). By using qPCR, protein expression analyses can be done to 
explore the physiological role of various channels in cardiomyocytes – in this case expression of 
calcium channels in LCHADD CMs will be assessed against normal, wildtype (WT) cells under 
normal or high fat media concentrations. In addition to this measure, the following list provides 
an overview of methodology that will be used to assess various patient specific iPSC-CM 
functionalities.  
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Patch Clamp: Patch clamps include high conformity intracellular electrical recordings from 
cardiomyocytes that can provide detailed and precise assessments of the electrophysiological 
properties of CMs. Sharp electrodes that can penetrate the membrane of CMs can measure 
membrane potential and thus, characterize action potentials.  
Multielectrode Array: This method includes a noninvasive and nonterminal method that will 
allow for long-term measurements of extracellular field potential signals from monolayers of 
hiPSC-CMs. CMs can be plated on the walls of the MEA plate containing electrodes and then, 
field potential can be measured. These field duration potentials ultimately equate and correlate 
roughly to the QT interval in an in-vivo ECG and the action potential duration (APD) in-vitro 
(Garg & Shrestha, 2018).  
Fluorescence Imaging: Fluorescence microscopy methods can use Ca2+ or voltage-sensitive dyes 
as a non-invasive method to measure intracellular ion fluctuations and voltage changes. A 
difficulty that exists with this method is the potential binding of dyes to intracellular molecules 
which can interfere with the normal functioning of the cell.  
Impedance: Functional assays based on cellular impedance which is an indirect measure of 
cardiac contractility, offers a noninvasive, label-free, and high throughput analysis method (MF, 
SD, L, CW, & KL, 2015). Cells are seeded onto a multiwall cell culture plate that contains gold 
film electrodes embedded onto the bottom of the wells. The mechanical displacement of the cells 
during cardiomyocyte contraction is measured as variation in impedance otherwise measured as 
a resistance in a current which also directly correlates with beating frequency. 
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Figure 2. Platforms for functional analysis of human induced pluripotent stem cell-derived 
cardiomyocytes (hiPSC-CMs). Graphical illustration summarizing different methods currently 
used for hiPSC-CM functionality analyses. Patch clamp (A); multielectrode array (B; MEA); 
fluorescence imaging (C); impedance (D). Representative MEA 78,79 and fluorescence imaging 
80,81 traces (American Heart Association, 2015).  
Without the presence of structural heart disease, this exploration aims to explore the life 
threatening ventricular arrests that can lead to sudden cardiac death in LCHADD patients 
especially in the younger adult population which can possibly arise as a result of concurrent 
defects found in specialized membrane proteins called ion channels as suspected by some other 
works of research (Garg, 2018). Changes in the function or expression of these channels in 
cardiomyocytes could potentially disrupt the highly intricate and orchestrated electrical activity 
of the heart which is why this study focuses on assessing the various functional platforms of 
cardiomyocytes.   
Results  
 A case series study was done to evaluate for cardiac risk factors by comparing LCHADD 
patients who have experienced sudden cardiac arrest events (N=5) against those who have not 
(denoted ‘controls,’ N=5). A plethora of hospitalization and general medical records were 
reviewed including diagnostic testing, electrocardiograph (ECG) tests, heart rhythm strips, 
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plasma acylcarnitine levels, as well as the curation of a retrospective chart review of patient 
medical records including metabolic panels, clinician notes, electrolytes, and specific symptoms 
that were reported upon admission. The table below is followed by specific case details of each 
of the young adult patients that experienced sudden cardiac death in the study. 
 
Figure 3. A general overview of LCHADD patient data divided by individuals who experienced 
sudden cardiac arrest and those who did not. Patients in red text indicate cases who experienced 
SCD, and those in black are ‘controls’ who have not yet experienced a SCD event.  
 
Case #1 was 21 years of age at their first cardiac event which included episodes of 
ventricular fibrillations, sinus tachycardia, long-QT syndrome and potential suspicions of 
torsades de pointes. Other medical histories regarding classic symptoms of LCHAD include 
blindness, and neuropathy. This patient was diagnosed with LCHADD at 6 months of age 
following initial presentation to the emergency room with jaundice, failure to thrive, and 
Cardiac
Arrhythmias
Case #1 M YES 21 27
VF, VT, long 
QT, TdP
4-5 days prior 
nausea, 
-- Blindness, neuropathy
Case #2 M YES 20 26 VF, VT
300,000 CK, acute 
kidney injury, 
seizure activity, was 
in rhabdo upon 
adm., 4-5 days prior 
nausea
--
300,000 CK, acute kidney 
injury, seizure activity, 
macular thinning
Case #3 M YES 19 --
VF, VT, long 
QT
Anxiety and  panic 
attacks upon pres.
ICU adm. @ 8mo 
hypoglycemia
Retinitis, blindness, 
anxiety, panic attacks
Case #4 M YES 15 26 VF, VT
Found with seizure 
activity
Pre-mature birth
Retinopathy, 
hydrocephalus
Case #5 F YES 19 -- N/A
Was found 
unconscious in 
basement and 
pronounced deceased 
ICU adm. @ 4 
months, mother w/ 
HELLP
Retinopathy, increased 
LFTs, rhabdomyolysis
Control #1 F NO -- 23
ST 
abnormalities, 
 Diastolic 
dysfunction
-- Coma @ 9mo
Rhabdomyolysis, periph. 
retinopathy and neuropathy
Control #2 M NO -- 19 PVCs, SVT
Syncope, AVNRT, 
respiratory illness, S-
ICD
Coma @ 10mo Fatty liver,
Control #3 M NO -- 24 N/A --
ICU adm. @6mo 
hypoglycemia
Rhabdomyolysis, myopathy
Control #4 F NO -- 26 N/A --
ICU adm. @ 4 
months, mother w/ 
HELLP
Rhabdomyolysis, 
retinopathy, ear infections
Control #5
Patients
Course of 
Pregnancy
Other Medical History
F NO -- 23 N/A --
Premature 2mo, 
ICU adm.
Rhabdomyolysis 
Gender Cardiac Event Age at Event
Current 
Age
Significant 
Admission Notes
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decreased activity. The diagnosis was confirmed by liver biopsy and subsequent fatty acid 
oxidation flux studies in cultured hepatocytes with low LCHAD enzymatic activity. His 
subsequent clinical history is remarkable for frequent recurrent rhabdomyolysis requiring 
hospitalization multiple times per year throughout his lifetime. CKs range from 4000 to >40,000 
during these episodes. Prior to their admission, the patient had increased levels of CK at around 
2,700 U/L, and had been vomiting for approximately 7 hours prior to their hospitalization. Upon 
admission, the patient was experiencing a significant decrease in cognition characterized by 
decreased comprehension, and expression of language with delayed response and decreased 
organization of language. The patient was found to be in torsade’s de pointes after one cardiac 
event. An echocardiogram done on the patient showed ejection fraction down at 45-50%, with a 
mildly enlarged right ventricle, and mildly reduced RV systolic function. Right ventricular 
systolic pressure was noted to be calculated at 30.6 mmHg. Along with cardiac arrest-ventricular 
fibrillation, acute respiratory failure was reported which required intubation and mechanical 
ventilation. Additionally, the patient was found to be in sepsis secondary to aspiration 
pneumonia. Case #1 was prescribed MCT oil and levocarnitine and is presumed to have been 
compliant with this upon the time of admission.  
Case #2 was 20 years of age at their first cardiac event which included ventricular 
fibrillation bursts followed by a ventricular tachycardia arrest. In prior history, the patient was 
known to have multiple hospital admissions for episodes of rhabdomyolysis. Before their event, 
case #2 had been experiencing 4-5 days of nausea prior to their admission similar to case #1. Of 
significant note was that case #2 was the only patient who was found to be in a severe case of 
rhabdomyolysis upon admission with CK levels upwards of 300,000 U/L. Upon review of an 
echocardiogram, the patient was noted to have systolic heart failure. The patient was also treated 
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for anemia, pleural effusions, antibiotic associated diarrhea, and epistaxis. Their ejection fraction 
demonstrated only mild decrease in systolic function and was suspected that some of their 
cardiomyopathy is related to metabolic disturbances exacerbated by rhabdomyolysis however, 
yet an unknown underlying result of LCHADD. The patient’s arrests had occurred in the setting 
of acidosis and hyperkalemia related to rhabdomyolysis. Case #2 had been prescribed dietary 
supplements including MCT oil, levocarnitine, DHA, vitamin D, and magnesium/calcium but, 
was not compliant with these prescriptions at the time of the event.  
Case #3 was 19 years of age at their first cardiac event. This patient had presented with 
an ICU admission at 8 months of age to be treated for hypoglycemia and was also diagnosed 
with LCHADD. In prior history, the patient has experienced retinopathy and blindness, 
generalized anxiety, panic attacks, and admitted for various hospitalizations due to episodes of 
rhabdomyolysis. The patient presented with an acute loss of consciousness and was found to be 
in ventricular fibrillation upon arriving to the emergency department at their first cardiac event. 
The patient was riding in a car as they complained of a headache, and then became unresponsive. 
They were given 2 rounds of epinephrine as well as cardioversion and then transferred to another 
medical center where the patient had several episodes of pulseless ventricular tachycardia which 
resulted in the administration of amiodarone and subsequently resulted in seizure activity. 
Following the seizures, the patient was administered fosphenytoin. An echocardiogram showed 
normal left ventricular size with moderate to marked depression of systolic function as well as 
normal right ventricular size with moderate depression of systolic function with no significant 
valvular or pericardial issues. Following an evaluation by the hospital’s cardiology and 
electrophysiology unit, an automatic implantable cardioverter defibrillator was placed one week 
after their first admission. The patient had a past medical history of premature retinopathy and a 
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hydrocephalus which required a VP shunt. The patient was not on any home medications prior to 
hospitalization including any dietary supplements.  
Case #4 was 15 years of age at their first cardiac event which presented with ventricular 
fibrillation and tachycardia arrest, and prolonged QTc interval. The patient had a pre-mature 
birth at approximately 10 months with a prior history of retinopathy and hydrocephalus. Upon 
admission, case #4 experienced an acute deterioration of EF from 50% to 20% over the course of 
1 week during the admission which had ultimately led to cardiac arrest, 30 minutes of CPR, 
intubation for 11 days and ECMO therapy. They were hemodynamically stable since their 
extubation however the patient now has hoarseness and dysphagia to thin liquids. Upon 
hospitalization, the patient was noted to have a short run of VT (6 beats), and an evaluation of an 
ECHO that showed poor function. The patient had numerous hospitalization due to recurring 
cases of rhabdomyolysis. Their sudden cardiac arrest event was in the presence of an episode of 
rhabdomyolysis. The patient had also been experiencing retinitis, joint pain, blindness, and 
abnormality of gait. Of significant note is the patients recurring anxiety/diaphoresis/weakness 
and recent physical deterioration and decreased mobility. Case #4 was prescribed levocarnitine, 
MCT oil, and vitamin D and E tablets however it is unclear whether the patient was compliant 
with the medications upon hospitalization for their cardiac death event.  
Case #5 was 19 years of age when they were unexpectedly found dead in the basement of 
their house. An autopsy report determined that the specific cause was unclear although due to an 
unknown, underlying condition of LCHADD. The patient had a classical presentation during 
early infancy with an ICU admission at four months of age with retinopathy and frequent 
episodes of rhabdomyolysis. The patient’s mother had also died from increased LFTs due to 
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HELLP syndrome, Case #5 was prescribed MCT oil, carnitine, cod liver oil, and vitamin A, 
however, was not compliant with these in recent history.  
Results for each of the sudden cardiac arrest events were compared against five ‘controls’ 
who were also young adult patients with LCHADD but, had not yet experienced any sudden 
cardiac arrest events besides control #3 who had experienced some premature ventricular 
contractions but no, complete cardiac death as experienced by all 5 cases in the study. All of the 
controls are of similar age to the cases who experienced sudden cardiac arrest however, there 
does not appear to be any significant differences in the course of the disease between the two 
populations. Both populations were prescribed and ordered to follow a strict diet and upon 
retrospective case review, 3/5 those who experienced sudden cardiac reported failure to keep up 
with their medications upon the time of admission for their cardiac events. Figure 4 illustrates the 
supplements that were prescribed to the two populations and their compliance. Both groups were 
prescribed similar dietary supplements and this does not appear to be influencing the nature of 
cardiac arrythmias in patients. To supplement this data, elevated carnitine levels can be seen in 
cases as indicated by the increased carnitine ratios in figure 4 that depict cases to have ratios >1 
and controls with ratios <1. These results are limited in their ability to deduce sound conclusions 
of why cases are more likely than controls to experience sudden cardiac arrest due to the time 
upon when certain medical records were measured in patients; not all data points were retrieved 
upon initial hospital admissions and, some data points relied on prior test results which could 
have been extremely different to levels upon presentation of a cardiac arrest event.  
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Figure 4. A list of the prescribed supplements to be taken by the LCHADD patients included in 
the study. 
 
Figure 5. Various measures of carnitine levels in LCHADD patients (μMol/L). Patients in red are 
patients who are cases and those in blue are ‘control’ patients who have not yet experienced 
sudden cardiac death. 
Anticipated Effects on Mitochondrial Function in iPSC-CMs & 
Discussion 
 
Due to the impacts of COVID-19, further generation of cardiomyocytes was halted in the 
prior months prohibiting the advancement of this data acquisition. However, anticipated impacts, 
results and the rationale behind the exploration of various mitochondrial functions in LCHAD 
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deficient cardiomyocytes is described below. These various parameters and measurements are 
compared between LCHAD deficient cardiomyocytes and normal cardiomyocytes derived from 
wild type (WT) cells that are healthy.  
 For the exploration of bioenergetic impacts. we anticipate that LCHADD cardiomyocytes 
will have similar oxygen consumption and ATP production as WT cells under high glucose 
conditions. However, we hypothesize the LCHADD cardiomyocytes will have lower O2 
consumption and ATP production compared to WT cells under conditions of low glucose/fatty 
acid supplemented media. 
 Following the completion of various functional assessment platforms, we anticipate that 
LCHADD cardiomyocytes will have similar functional parameters during patch clamp, MEA, 
fluorescent imaging and impedance as WT cells under high glucose conditions. However, we 
hypothesize the LCHADD cardiomyocytes will have altered functional analysis with lower 
contractile force compared to WT cells under conditions of low glucose/fatty acid supplemented 
media. 
 As described, some areas of research suggest that toxic byproducts can accumulate as a 
result of FAODs. With this consideration, we anticipate LCHADD cardiomyocytes will have 
elevated long-chain, 3-OH acylcarnitines in all conditions but that these metabolites will increase 
dramatically during low glucose/fatty acid supplemented media conditions. Elevated partially 
oxidized metabolites will be associated with increased ROS, acidosis, and increased lactate. 
It is possible other mechanisms in addition to energetic deficiencies could contribute to 
the pathophysiology of the severe cardiac manifestations reported here in young adult LCHADD 
patients. Mitochondrial stress and accumulation of toxic metabolites such as long-chain hydroxy 
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FAs or carnitine due to inborn errors of metabolism that could potentially lead to severe cardiac 
death in LCHADD patients (Spiekerkoetter & Wood, 2010). Wajner summarized the potential 
mechanisms that affect energy homeostasis and suggests a potential explanation of the 
pathophysiology of the disease. Mechanisms included altered redox reactions, fatty acid 
accumulation, acidity, calcium and potassium homeostasis, as well as derangements in 
bioenergetics. Understanding the role of accumulated fatty acids metabolites as a crucial player 
in altered bioenergetics of the cells as well as its role in inducing mitochondrial dysfunction are 
crucial in understanding why LCHAD deficient patients may develop these dysregulations. In 
the study by Wajner, alterations were seen in biochemical processes in mice liver, muscle, and 
heart tissues. If cardiomyocytes with a mature phenotype were successfully developed, some 
anticipated results of the assessment of cardiomyocytes could include a decrease in force of 
contraction, decreased calcium retention capacities, erratic beating patterns, and severe 
mitochondrial defects. 
 Typically, upon diagnosis and treatment in the pre- and post-natal stages of LCHADD, 
cardiomyopathy is typically resolved and patients go on to report normal cardiac function in 
childhood. This exploration of sudden ventricular tachycardia in this young adult population with 
LCHADD ranging in ages between 16 and 23 years is one that is unique and not currently 
described in the literature. Following the retrospective case study review, we report minor 
differences in supplements and carnitine levels between cases and controls as well as minor 
electrolyte derangements that were seen. However, we hypothesize that unidentified underlying 
cardiac risk factors that increase the risk for sudden cardiac death continue to exist. It is 
important to consider that this study exemplifies that sudden cardiac arrest can occur in any 
setting and is not exacerbated through other severe symptoms often accompanied with LCHADD 
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patients including episodes of rhabdomyolysis or varied adherence to supplements and diets 
prescribed. Applications and exploration of this topic using stem cell technology to generate 
beating cardiomyocytes provides a promising model to investigate this severe cardiac 
manifestation and its potential molecular mechanisms. Future directions of this study will pick 
up where we left off before the spread of COVID-19 to produce phenotypically mature 
cardiomyocytes as well as to obtain thorough and complete data for this critically vulnerable 
population. Future anticipated clinical trials that have been approved by the IRB will include 
data from cardiac magnetic resonance imaging of the heart, results of ECG bicycle exercise 
stress tests, measures of acylcarnitine levels before and after these tests, and blood draws to 
perform thorough laboratory studies and measurement of patients’ electrolytes, glucose, insulin, 
creatine kinase, free fatty acids, lactate, pyruvate, ketones and plasma/serum acylcarnitine levels. 
Following the acquisition of sound patient data through clinical trials along with the 
establishment of a mature cardiomyocyte model to explore potential mechanisms, our research 
group will further contribute to the limited understanding of this very severe cardiac 
manifestation exhibited in patients with FAODs like LCHADD.   
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